nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—ABCB1—hematologic cancer	0.0435	1	CbGaD
Doxepin—ORM1—Imatinib—hematologic cancer	0.0278	0.054	CbGbCtD
Doxepin—CYP1A2—Anagrelide—hematologic cancer	0.0225	0.0437	CbGbCtD
Doxepin—CYP2C9—Bexarotene—hematologic cancer	0.014	0.0273	CbGbCtD
Doxepin—ABCB1—Lenalidomide—hematologic cancer	0.0136	0.0265	CbGbCtD
Doxepin—CYP2D6—Lomustine—hematologic cancer	0.0119	0.0232	CbGbCtD
Doxepin—CYP1A2—Carmustine—hematologic cancer	0.0118	0.0229	CbGbCtD
Doxepin—CYP2C9—Idarubicin—hematologic cancer	0.0116	0.0226	CbGbCtD
Doxepin—CYP2D6—Idarubicin—hematologic cancer	0.0106	0.0207	CbGbCtD
Doxepin—CYP2C19—Bortezomib—hematologic cancer	0.0103	0.0201	CbGbCtD
Doxepin—CYP1A2—Methoxsalen—hematologic cancer	0.01	0.0195	CbGbCtD
Doxepin—CYP1A2—Bortezomib—hematologic cancer	0.00954	0.0185	CbGbCtD
Doxepin—CYP1A2—Daunorubicin—hematologic cancer	0.00913	0.0177	CbGbCtD
Doxepin—CYP2D6—Hydroxyurea—hematologic cancer	0.00904	0.0176	CbGbCtD
Doxepin—CYP2C19—Thalidomide—hematologic cancer	0.00901	0.0175	CbGbCtD
Doxepin—CYP1A2—Alitretinoin—hematologic cancer	0.00894	0.0174	CbGbCtD
Doxepin—CYP2C9—Bortezomib—hematologic cancer	0.0086	0.0167	CbGbCtD
Doxepin—CYP2C19—Teniposide—hematologic cancer	0.0086	0.0167	CbGbCtD
Doxepin—CYP1A2—Thalidomide—hematologic cancer	0.00831	0.0162	CbGbCtD
Doxepin—CYP3A4—Bexarotene—hematologic cancer	0.00816	0.0159	CbGbCtD
Doxepin—ABCB1—Daunorubicin—hematologic cancer	0.00798	0.0155	CbGbCtD
Doxepin—CYP2C19—Ifosfamide—hematologic cancer	0.00793	0.0154	CbGbCtD
Doxepin—CYP2D6—Bortezomib—hematologic cancer	0.00786	0.0153	CbGbCtD
Doxepin—ABCB1—Alitretinoin—hematologic cancer	0.00782	0.0152	CbGbCtD
Doxepin—CYP3A4—Lomustine—hematologic cancer	0.00758	0.0147	CbGbCtD
Doxepin—CYP3A4—Busulfan—hematologic cancer	0.00758	0.0147	CbGbCtD
Doxepin—CYP2C19—Imatinib—hematologic cancer	0.00758	0.0147	CbGbCtD
Doxepin—CYP2C9—Thalidomide—hematologic cancer	0.00749	0.0146	CbGbCtD
Doxepin—CYP1A2—Dacarbazine—hematologic cancer	0.00715	0.0139	CbGbCtD
Doxepin—CYP2C9—Teniposide—hematologic cancer	0.00715	0.0139	CbGbCtD
Doxepin—CYP1A2—Imatinib—hematologic cancer	0.00699	0.0136	CbGbCtD
Doxepin—CYP3A4—Thiotepa—hematologic cancer	0.00676	0.0131	CbGbCtD
Doxepin—CYP2C9—Ifosfamide—hematologic cancer	0.0066	0.0128	CbGbCtD
Doxepin—CYP2C9—Imatinib—hematologic cancer	0.0063	0.0122	CbGbCtD
Doxepin—ABCB1—Imatinib—hematologic cancer	0.00611	0.0119	CbGbCtD
Doxepin—CYP2D6—Imatinib—hematologic cancer	0.00576	0.0112	CbGbCtD
Doxepin—CYP2C9—Nilotinib—hematologic cancer	0.00573	0.0111	CbGbCtD
Doxepin—CYP1A2—Dasatinib—hematologic cancer	0.00562	0.0109	CbGbCtD
Doxepin—ABCB1—Nilotinib—hematologic cancer	0.00556	0.0108	CbGbCtD
Doxepin—ABCB1—Vinorelbine—hematologic cancer	0.00551	0.0107	CbGbCtD
Doxepin—CYP3A4—Methoxsalen—hematologic cancer	0.00526	0.0102	CbGbCtD
Doxepin—CYP2D6—Nilotinib—hematologic cancer	0.00524	0.0102	CbGbCtD
Doxepin—CYP2D6—Vinorelbine—hematologic cancer	0.00519	0.0101	CbGbCtD
Doxepin—CYP3A4—Bortezomib—hematologic cancer	0.005	0.00972	CbGbCtD
Doxepin—CYP2C19—Prednisone—hematologic cancer	0.00499	0.0097	CbGbCtD
Doxepin—ABCB1—Dasatinib—hematologic cancer	0.00491	0.00954	CbGbCtD
Doxepin—ABCB1—Mitoxantrone—hematologic cancer	0.00485	0.00943	CbGbCtD
Doxepin—CYP3A4—Daunorubicin—hematologic cancer	0.00478	0.00929	CbGbCtD
Doxepin—ABCB1—Betamethasone—hematologic cancer	0.00432	0.0084	CbGbCtD
Doxepin—ABCB1—Gemcitabine—hematologic cancer	0.00428	0.00833	CbGbCtD
Doxepin—ABCB1—Prednisolone—hematologic cancer	0.00427	0.00829	CbGbCtD
Doxepin—CYP3A4—Cytarabine—hematologic cancer	0.00422	0.0082	CbGbCtD
Doxepin—CYP3A4—Teniposide—hematologic cancer	0.00416	0.00808	CbGbCtD
Doxepin—ABCB1—Prednisone—hematologic cancer	0.00403	0.00783	CbGbCtD
Doxepin—CYP3A4—Ifosfamide—hematologic cancer	0.00383	0.00745	CbGbCtD
Doxepin—ABCB1—Irinotecan—hematologic cancer	0.00382	0.00742	CbGbCtD
Doxepin—CYP3A4—Imatinib—hematologic cancer	0.00366	0.00712	CbGbCtD
Doxepin—CYP1A2—Etoposide—hematologic cancer	0.0035	0.0068	CbGbCtD
Doxepin—HRH4—hematopoietic system—hematologic cancer	0.00347	0.0859	CbGeAlD
Doxepin—CYP3A4—Ruxolitinib—hematologic cancer	0.00345	0.0067	CbGbCtD
Doxepin—ABCB1—Vinblastine—hematologic cancer	0.0034	0.0066	CbGbCtD
Doxepin—ABCB1—Vincristine—hematologic cancer	0.00334	0.00649	CbGbCtD
Doxepin—CYP3A4—Nilotinib—hematologic cancer	0.00333	0.00647	CbGbCtD
Doxepin—CYP3A4—Vinorelbine—hematologic cancer	0.0033	0.00642	CbGbCtD
Doxepin—CYP2C9—Cisplatin—hematologic cancer	0.00321	0.00623	CbGbCtD
Doxepin—CYP2D6—Vinblastine—hematologic cancer	0.0032	0.00622	CbGbCtD
Doxepin—CYP2C19—Dexamethasone—hematologic cancer	0.00312	0.00606	CbGbCtD
Doxepin—ABCB1—Cisplatin—hematologic cancer	0.00311	0.00605	CbGbCtD
Doxepin—ABCB1—Etoposide—hematologic cancer	0.00306	0.00594	CbGbCtD
Doxepin—CYP3A4—Triamcinolone—hematologic cancer	0.00302	0.00587	CbGbCtD
Doxepin—CYP3A4—Dasatinib—hematologic cancer	0.00294	0.00572	CbGbCtD
Doxepin—CYP3A4—Mitoxantrone—hematologic cancer	0.00291	0.00565	CbGbCtD
Doxepin—CYP2C9—Dexamethasone—hematologic cancer	0.00259	0.00504	CbGbCtD
Doxepin—CYP3A4—Betamethasone—hematologic cancer	0.00259	0.00503	CbGbCtD
Doxepin—CYP3A4—Prednisolone—hematologic cancer	0.00256	0.00497	CbGbCtD
Doxepin—ABCB1—Dexamethasone—hematologic cancer	0.00251	0.00489	CbGbCtD
Doxepin—CYP3A4—Prednisone—hematologic cancer	0.00241	0.00469	CbGbCtD
Doxepin—CYP2D6—Dexamethasone—hematologic cancer	0.00237	0.00461	CbGbCtD
Doxepin—HRH4—blood—hematologic cancer	0.0023	0.0569	CbGeAlD
Doxepin—CYP3A4—Irinotecan—hematologic cancer	0.00229	0.00445	CbGbCtD
Doxepin—HRH4—bone marrow—hematologic cancer	0.00222	0.0551	CbGeAlD
Doxepin—ABCB1—Doxorubicin—hematologic cancer	0.00209	0.00405	CbGbCtD
Doxepin—CYP3A4—Vinblastine—hematologic cancer	0.00203	0.00395	CbGbCtD
Doxepin—ABCB1—Methotrexate—hematologic cancer	0.00202	0.00393	CbGbCtD
Doxepin—CYP3A4—Vincristine—hematologic cancer	0.002	0.00389	CbGbCtD
Doxepin—CYP2D6—Doxorubicin—hematologic cancer	0.00197	0.00382	CbGbCtD
Doxepin—CYP3A4—Etoposide—hematologic cancer	0.00183	0.00356	CbGbCtD
Doxepin—CYP3A4—Dexamethasone—hematologic cancer	0.00151	0.00293	CbGbCtD
Doxepin—HRH2—hematopoietic system—hematologic cancer	0.00146	0.0361	CbGeAlD
Doxepin—CYP3A4—Doxorubicin—hematologic cancer	0.00125	0.00243	CbGbCtD
Doxepin—ORM1—hematopoietic system—hematologic cancer	0.00102	0.0254	CbGeAlD
Doxepin—CHRM4—testis—hematologic cancer	0.000975	0.0241	CbGeAlD
Doxepin—HRH2—blood—hematologic cancer	0.000964	0.0239	CbGeAlD
Doxepin—SLC6A4—hematopoietic system—hematologic cancer	0.000872	0.0216	CbGeAlD
Doxepin—HRH2—lung—hematologic cancer	0.000845	0.0209	CbGeAlD
Doxepin—HTR1A—hematopoietic system—hematologic cancer	0.000774	0.0192	CbGeAlD
Doxepin—CYP2C19—hematopoietic system—hematologic cancer	0.000723	0.0179	CbGeAlD
Doxepin—ADRA1A—hematopoietic system—hematologic cancer	0.000714	0.0177	CbGeAlD
Doxepin—KCNH2—hematopoietic system—hematologic cancer	0.000689	0.0171	CbGeAlD
Doxepin—ORM1—blood—hematologic cancer	0.000678	0.0168	CbGeAlD
Doxepin—ORM1—bone marrow—hematologic cancer	0.000656	0.0163	CbGeAlD
Doxepin—ORM1—lung—hematologic cancer	0.000594	0.0147	CbGeAlD
Doxepin—CYP1A2—hematopoietic system—hematologic cancer	0.00059	0.0146	CbGeAlD
Doxepin—SLC6A2—gonad—hematologic cancer	0.000584	0.0145	CbGeAlD
Doxepin—HRH2—lymph node—hematologic cancer	0.000578	0.0143	CbGeAlD
Doxepin—SLC6A4—blood—hematologic cancer	0.000578	0.0143	CbGeAlD
Doxepin—HTR2B—blood—hematologic cancer	0.000573	0.0142	CbGeAlD
Doxepin—CYP2C9—hematopoietic system—hematologic cancer	0.00056	0.0139	CbGeAlD
Doxepin—HRH1—hematopoietic system—hematologic cancer	0.000553	0.0137	CbGeAlD
Doxepin—ADRA2A—hematopoietic system—hematologic cancer	0.000543	0.0134	CbGeAlD
Doxepin—SLC6A4—lung—hematologic cancer	0.000506	0.0125	CbGeAlD
Doxepin—CHRM1—lung—hematologic cancer	0.000505	0.0125	CbGeAlD
Doxepin—HTR2B—lung—hematologic cancer	0.000502	0.0124	CbGeAlD
Doxepin—CYP2C19—blood—hematologic cancer	0.000479	0.0119	CbGeAlD
Doxepin—ADRA1A—blood—hematologic cancer	0.000473	0.0117	CbGeAlD
Doxepin—HTR2A—hematopoietic system—hematologic cancer	0.000461	0.0114	CbGeAlD
Doxepin—KCNH2—blood—hematologic cancer	0.000457	0.0113	CbGeAlD
Doxepin—ADRA2C—blood—hematologic cancer	0.000451	0.0112	CbGeAlD
Doxepin—SLC6A2—lung—hematologic cancer	0.000446	0.011	CbGeAlD
Doxepin—KCNH2—bone marrow—hematologic cancer	0.000442	0.0109	CbGeAlD
Doxepin—CYP3A4—hematopoietic system—hematologic cancer	0.000427	0.0106	CbGeAlD
Doxepin—CHRM3—testis—hematologic cancer	0.000426	0.0106	CbGeAlD
Doxepin—SLC6A2—testis—hematologic cancer	0.000421	0.0104	CbGeAlD
Doxepin—CYP2D6—hematopoietic system—hematologic cancer	0.00042	0.0104	CbGeAlD
Doxepin—ADRA2A—gonad—hematologic cancer	0.000413	0.0102	CbGeAlD
Doxepin—ORM1—lymph node—hematologic cancer	0.000407	0.0101	CbGeAlD
Doxepin—DRD2—lung—hematologic cancer	0.000406	0.0101	CbGeAlD
Doxepin—ADRA2C—lung—hematologic cancer	0.000395	0.00979	CbGeAlD
Doxepin—CYP1A2—blood—hematologic cancer	0.000391	0.00969	CbGeAlD
Doxepin—DRD2—testis—hematologic cancer	0.000383	0.0095	CbGeAlD
Doxepin—KCNH2—testis—hematologic cancer	0.000378	0.00936	CbGeAlD
Doxepin—ADRA2C—testis—hematologic cancer	0.000373	0.00923	CbGeAlD
Doxepin—CYP2C9—blood—hematologic cancer	0.000371	0.00919	CbGeAlD
Doxepin—ADRA2A—blood—hematologic cancer	0.00036	0.00891	CbGeAlD
Doxepin—HTR2A—gonad—hematologic cancer	0.000351	0.00869	CbGeAlD
Doxepin—HTR2B—lymph node—hematologic cancer	0.000343	0.0085	CbGeAlD
Doxepin—CYP1A2—lung—hematologic cancer	0.000343	0.00849	CbGeAlD
Doxepin—HRH1—lung—hematologic cancer	0.000321	0.00795	CbGeAlD
Doxepin—ADRA2A—lung—hematologic cancer	0.000315	0.00781	CbGeAlD
Doxepin—HTR2A—blood—hematologic cancer	0.000306	0.00757	CbGeAlD
Doxepin—SLC6A2—lymph node—hematologic cancer	0.000305	0.00756	CbGeAlD
Doxepin—HRH1—testis—hematologic cancer	0.000303	0.0075	CbGeAlD
Doxepin—ABCB1—hematopoietic system—hematologic cancer	0.000302	0.00749	CbGeAlD
Doxepin—ADRA2A—testis—hematologic cancer	0.000297	0.00737	CbGeAlD
Doxepin—CYP3A4—blood—hematologic cancer	0.000283	0.00701	CbGeAlD
Doxepin—CYP2D6—blood—hematologic cancer	0.000279	0.0069	CbGeAlD
Doxepin—KCNH2—lymph node—hematologic cancer	0.000274	0.00678	CbGeAlD
Doxepin—ADRA2C—lymph node—hematologic cancer	0.00027	0.00669	CbGeAlD
Doxepin—HTR2A—lung—hematologic cancer	0.000268	0.00664	CbGeAlD
Doxepin—HTR2A—testis—hematologic cancer	0.000253	0.00626	CbGeAlD
Doxepin—CYP2D6—testis—hematologic cancer	0.00023	0.00571	CbGeAlD
Doxepin—ABCB1—gonad—hematologic cancer	0.00023	0.0057	CbGeAlD
Doxepin—HRH1—lymph node—hematologic cancer	0.000219	0.00544	CbGeAlD
Doxepin—ADRA2A—lymph node—hematologic cancer	0.000216	0.00534	CbGeAlD
Doxepin—ABCB1—blood—hematologic cancer	0.0002	0.00496	CbGeAlD
Doxepin—ABCB1—bone marrow—hematologic cancer	0.000194	0.0048	CbGeAlD
Doxepin—Thiothixene—SLC22A1—hematologic cancer	0.000186	0.154	CrCbGaD
Doxepin—ABCB1—lung—hematologic cancer	0.000176	0.00435	CbGeAlD
Doxepin—ABCB1—testis—hematologic cancer	0.000166	0.00411	CbGeAlD
Doxepin—Clomipramine—GSTP1—hematologic cancer	0.000159	0.132	CrCbGaD
Doxepin—Diphenhydramine—SLC22A1—hematologic cancer	0.000133	0.11	CrCbGaD
Doxepin—ABCB1—lymph node—hematologic cancer	0.00012	0.00298	CbGeAlD
Doxepin—Desipramine—SLC22A1—hematologic cancer	0.000118	0.0982	CrCbGaD
Doxepin—Imipramine—SLC22A1—hematologic cancer	0.0001	0.0833	CrCbGaD
Doxepin—Oxcarbazepine—ALB—hematologic cancer	7.8e-05	0.0647	CrCbGaD
Doxepin—Thiothixene—ALB—hematologic cancer	5.67e-05	0.047	CrCbGaD
Doxepin—Clomipramine—ALB—hematologic cancer	4.48e-05	0.0372	CrCbGaD
Doxepin—Nortriptyline—ALB—hematologic cancer	4.38e-05	0.0363	CrCbGaD
Doxepin—Clomipramine—ABCB1—hematologic cancer	4.28e-05	0.0355	CrCbGaD
Doxepin—Chlorprothixene—ABCB1—hematologic cancer	4.26e-05	0.0353	CrCbGaD
Doxepin—Trimipramine—ABCB1—hematologic cancer	3.93e-05	0.0326	CrCbGaD
Doxepin—Promethazine—ABCB1—hematologic cancer	3.79e-05	0.0314	CrCbGaD
Doxepin—Desipramine—ABCB1—hematologic cancer	3.44e-05	0.0285	CrCbGaD
Doxepin—Amitriptyline—ALB—hematologic cancer	3.04e-05	0.0252	CrCbGaD
Doxepin—Imipramine—ABCB1—hematologic cancer	2.92e-05	0.0242	CrCbGaD
Doxepin—Amitriptyline—ABCB1—hematologic cancer	2.9e-05	0.0241	CrCbGaD
Doxepin—Feeling abnormal—Betamethasone—hematologic cancer	2.03e-05	7.29e-05	CcSEcCtD
Doxepin—Flushing—Doxorubicin—hematologic cancer	2.02e-05	7.28e-05	CcSEcCtD
Doxepin—Cardiac disorder—Doxorubicin—hematologic cancer	2.02e-05	7.28e-05	CcSEcCtD
Doxepin—Flatulence—Epirubicin—hematologic cancer	2.02e-05	7.27e-05	CcSEcCtD
Doxepin—Tension—Epirubicin—hematologic cancer	2.01e-05	7.24e-05	CcSEcCtD
Doxepin—Gastrointestinal pain—Betamethasone—hematologic cancer	2.01e-05	7.23e-05	CcSEcCtD
Doxepin—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.01e-05	7.23e-05	CcSEcCtD
Doxepin—Dysgeusia—Epirubicin—hematologic cancer	2.01e-05	7.23e-05	CcSEcCtD
Doxepin—Hypersensitivity—Triamcinolone—hematologic cancer	2e-05	7.18e-05	CcSEcCtD
Doxepin—Nervousness—Epirubicin—hematologic cancer	1.99e-05	7.17e-05	CcSEcCtD
Doxepin—Back pain—Epirubicin—hematologic cancer	1.98e-05	7.14e-05	CcSEcCtD
Doxepin—Angiopathy—Doxorubicin—hematologic cancer	1.98e-05	7.12e-05	CcSEcCtD
Doxepin—Malaise—Methotrexate—hematologic cancer	1.98e-05	7.11e-05	CcSEcCtD
Doxepin—Dizziness—Etoposide—hematologic cancer	1.98e-05	7.1e-05	CcSEcCtD
Doxepin—Muscle spasms—Epirubicin—hematologic cancer	1.97e-05	7.09e-05	CcSEcCtD
Doxepin—Immune system disorder—Doxorubicin—hematologic cancer	1.97e-05	7.08e-05	CcSEcCtD
Doxepin—Vertigo—Methotrexate—hematologic cancer	1.97e-05	7.08e-05	CcSEcCtD
Doxepin—Mediastinal disorder—Doxorubicin—hematologic cancer	1.97e-05	7.07e-05	CcSEcCtD
Doxepin—Leukopenia—Methotrexate—hematologic cancer	1.96e-05	7.06e-05	CcSEcCtD
Doxepin—Chills—Doxorubicin—hematologic cancer	1.96e-05	7.04e-05	CcSEcCtD
Doxepin—Urticaria—Dexamethasone—hematologic cancer	1.95e-05	7.02e-05	CcSEcCtD
Doxepin—Urticaria—Betamethasone—hematologic cancer	1.95e-05	7.02e-05	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.95e-05	7.02e-05	CcSEcCtD
Doxepin—Dizziness—Prednisolone—hematologic cancer	1.95e-05	7.01e-05	CcSEcCtD
Doxepin—Arrhythmia—Doxorubicin—hematologic cancer	1.95e-05	7.01e-05	CcSEcCtD
Doxepin—Asthenia—Triamcinolone—hematologic cancer	1.94e-05	6.99e-05	CcSEcCtD
Doxepin—Abdominal pain—Dexamethasone—hematologic cancer	1.94e-05	6.99e-05	CcSEcCtD
Doxepin—Body temperature increased—Betamethasone—hematologic cancer	1.94e-05	6.99e-05	CcSEcCtD
Doxepin—Abdominal pain—Betamethasone—hematologic cancer	1.94e-05	6.99e-05	CcSEcCtD
Doxepin—Body temperature increased—Dexamethasone—hematologic cancer	1.94e-05	6.99e-05	CcSEcCtD
Doxepin—Nausea—Cisplatin—hematologic cancer	1.94e-05	6.97e-05	CcSEcCtD
Doxepin—Insomnia—Prednisone—hematologic cancer	1.94e-05	6.96e-05	CcSEcCtD
Doxepin—Vision blurred—Epirubicin—hematologic cancer	1.93e-05	6.95e-05	CcSEcCtD
Doxepin—Alopecia—Doxorubicin—hematologic cancer	1.93e-05	6.93e-05	CcSEcCtD
Doxepin—Paraesthesia—Prednisone—hematologic cancer	1.92e-05	6.91e-05	CcSEcCtD
Doxepin—Pruritus—Triamcinolone—hematologic cancer	1.92e-05	6.89e-05	CcSEcCtD
Doxepin—Cough—Methotrexate—hematologic cancer	1.91e-05	6.88e-05	CcSEcCtD
Doxepin—Mental disorder—Doxorubicin—hematologic cancer	1.91e-05	6.87e-05	CcSEcCtD
Doxepin—Ill-defined disorder—Epirubicin—hematologic cancer	1.9e-05	6.85e-05	CcSEcCtD
Doxepin—Convulsion—Methotrexate—hematologic cancer	1.9e-05	6.83e-05	CcSEcCtD
Doxepin—Vomiting—Etoposide—hematologic cancer	1.9e-05	6.83e-05	CcSEcCtD
Doxepin—Erythema—Doxorubicin—hematologic cancer	1.9e-05	6.83e-05	CcSEcCtD
Doxepin—Malnutrition—Doxorubicin—hematologic cancer	1.9e-05	6.83e-05	CcSEcCtD
Doxepin—Anaemia—Epirubicin—hematologic cancer	1.9e-05	6.82e-05	CcSEcCtD
Doxepin—Agitation—Epirubicin—hematologic cancer	1.89e-05	6.78e-05	CcSEcCtD
Doxepin—Dyspepsia—Prednisone—hematologic cancer	1.88e-05	6.78e-05	CcSEcCtD
Doxepin—Rash—Etoposide—hematologic cancer	1.88e-05	6.77e-05	CcSEcCtD
Doxepin—Dermatitis—Etoposide—hematologic cancer	1.88e-05	6.77e-05	CcSEcCtD
Doxepin—Headache—Etoposide—hematologic cancer	1.87e-05	6.73e-05	CcSEcCtD
Doxepin—Flatulence—Doxorubicin—hematologic cancer	1.87e-05	6.73e-05	CcSEcCtD
Doxepin—Arthralgia—Methotrexate—hematologic cancer	1.87e-05	6.71e-05	CcSEcCtD
Doxepin—Myalgia—Methotrexate—hematologic cancer	1.87e-05	6.71e-05	CcSEcCtD
Doxepin—Chest pain—Methotrexate—hematologic cancer	1.87e-05	6.71e-05	CcSEcCtD
Doxepin—Tension—Doxorubicin—hematologic cancer	1.86e-05	6.7e-05	CcSEcCtD
Doxepin—Decreased appetite—Prednisone—hematologic cancer	1.86e-05	6.69e-05	CcSEcCtD
Doxepin—Dysgeusia—Doxorubicin—hematologic cancer	1.86e-05	6.69e-05	CcSEcCtD
Doxepin—Rash—Prednisolone—hematologic cancer	1.86e-05	6.68e-05	CcSEcCtD
Doxepin—Dermatitis—Prednisolone—hematologic cancer	1.86e-05	6.68e-05	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.85e-05	6.67e-05	CcSEcCtD
Doxepin—Malaise—Epirubicin—hematologic cancer	1.85e-05	6.65e-05	CcSEcCtD
Doxepin—Fatigue—Prednisone—hematologic cancer	1.85e-05	6.64e-05	CcSEcCtD
Doxepin—Headache—Prednisolone—hematologic cancer	1.85e-05	6.64e-05	CcSEcCtD
Doxepin—Discomfort—Methotrexate—hematologic cancer	1.84e-05	6.63e-05	CcSEcCtD
Doxepin—Nervousness—Doxorubicin—hematologic cancer	1.84e-05	6.63e-05	CcSEcCtD
Doxepin—Vertigo—Epirubicin—hematologic cancer	1.84e-05	6.63e-05	CcSEcCtD
Doxepin—Syncope—Epirubicin—hematologic cancer	1.84e-05	6.62e-05	CcSEcCtD
Doxepin—Leukopenia—Epirubicin—hematologic cancer	1.84e-05	6.61e-05	CcSEcCtD
Doxepin—Back pain—Doxorubicin—hematologic cancer	1.84e-05	6.6e-05	CcSEcCtD
Doxepin—Constipation—Prednisone—hematologic cancer	1.83e-05	6.58e-05	CcSEcCtD
Doxepin—Muscle spasms—Doxorubicin—hematologic cancer	1.83e-05	6.56e-05	CcSEcCtD
Doxepin—Palpitations—Epirubicin—hematologic cancer	1.81e-05	6.52e-05	CcSEcCtD
Doxepin—Confusional state—Methotrexate—hematologic cancer	1.8e-05	6.49e-05	CcSEcCtD
Doxepin—Loss of consciousness—Epirubicin—hematologic cancer	1.8e-05	6.49e-05	CcSEcCtD
Doxepin—Dizziness—Triamcinolone—hematologic cancer	1.79e-05	6.44e-05	CcSEcCtD
Doxepin—Cough—Epirubicin—hematologic cancer	1.79e-05	6.44e-05	CcSEcCtD
Doxepin—Vision blurred—Doxorubicin—hematologic cancer	1.79e-05	6.43e-05	CcSEcCtD
Doxepin—Convulsion—Epirubicin—hematologic cancer	1.78e-05	6.39e-05	CcSEcCtD
Doxepin—Infection—Methotrexate—hematologic cancer	1.78e-05	6.39e-05	CcSEcCtD
Doxepin—Nausea—Etoposide—hematologic cancer	1.77e-05	6.38e-05	CcSEcCtD
Doxepin—Hypertension—Epirubicin—hematologic cancer	1.77e-05	6.37e-05	CcSEcCtD
Doxepin—Feeling abnormal—Prednisone—hematologic cancer	1.76e-05	6.35e-05	CcSEcCtD
Doxepin—Asthenia—Dexamethasone—hematologic cancer	1.76e-05	6.34e-05	CcSEcCtD
Doxepin—Asthenia—Betamethasone—hematologic cancer	1.76e-05	6.34e-05	CcSEcCtD
Doxepin—Ill-defined disorder—Doxorubicin—hematologic cancer	1.76e-05	6.33e-05	CcSEcCtD
Doxepin—Nervous system disorder—Methotrexate—hematologic cancer	1.75e-05	6.31e-05	CcSEcCtD
Doxepin—Anaemia—Doxorubicin—hematologic cancer	1.75e-05	6.31e-05	CcSEcCtD
Doxepin—Thrombocytopenia—Methotrexate—hematologic cancer	1.75e-05	6.3e-05	CcSEcCtD
Doxepin—Gastrointestinal pain—Prednisone—hematologic cancer	1.75e-05	6.3e-05	CcSEcCtD
Doxepin—Nausea—Prednisolone—hematologic cancer	1.75e-05	6.29e-05	CcSEcCtD
Doxepin—Chest pain—Epirubicin—hematologic cancer	1.75e-05	6.28e-05	CcSEcCtD
Doxepin—Myalgia—Epirubicin—hematologic cancer	1.75e-05	6.28e-05	CcSEcCtD
Doxepin—Arthralgia—Epirubicin—hematologic cancer	1.75e-05	6.28e-05	CcSEcCtD
Doxepin—Agitation—Doxorubicin—hematologic cancer	1.74e-05	6.27e-05	CcSEcCtD
Doxepin—Anxiety—Epirubicin—hematologic cancer	1.74e-05	6.26e-05	CcSEcCtD
Doxepin—Pruritus—Betamethasone—hematologic cancer	1.74e-05	6.26e-05	CcSEcCtD
Doxepin—Pruritus—Dexamethasone—hematologic cancer	1.74e-05	6.26e-05	CcSEcCtD
Doxepin—Skin disorder—Methotrexate—hematologic cancer	1.74e-05	6.25e-05	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.73e-05	6.24e-05	CcSEcCtD
Doxepin—Hyperhidrosis—Methotrexate—hematologic cancer	1.73e-05	6.22e-05	CcSEcCtD
Doxepin—Discomfort—Epirubicin—hematologic cancer	1.73e-05	6.21e-05	CcSEcCtD
Doxepin—Vomiting—Triamcinolone—hematologic cancer	1.72e-05	6.2e-05	CcSEcCtD
Doxepin—Malaise—Doxorubicin—hematologic cancer	1.71e-05	6.16e-05	CcSEcCtD
Doxepin—Rash—Triamcinolone—hematologic cancer	1.71e-05	6.14e-05	CcSEcCtD
Doxepin—Dry mouth—Epirubicin—hematologic cancer	1.71e-05	6.14e-05	CcSEcCtD
Doxepin—Dermatitis—Triamcinolone—hematologic cancer	1.71e-05	6.14e-05	CcSEcCtD
Doxepin—Vertigo—Doxorubicin—hematologic cancer	1.71e-05	6.13e-05	CcSEcCtD
Doxepin—Anorexia—Methotrexate—hematologic cancer	1.71e-05	6.13e-05	CcSEcCtD
Doxepin—Syncope—Doxorubicin—hematologic cancer	1.7e-05	6.12e-05	CcSEcCtD
Doxepin—Urticaria—Prednisone—hematologic cancer	1.7e-05	6.12e-05	CcSEcCtD
Doxepin—Leukopenia—Doxorubicin—hematologic cancer	1.7e-05	6.11e-05	CcSEcCtD
Doxepin—Headache—Triamcinolone—hematologic cancer	1.7e-05	6.1e-05	CcSEcCtD
Doxepin—Abdominal pain—Prednisone—hematologic cancer	1.69e-05	6.09e-05	CcSEcCtD
Doxepin—Body temperature increased—Prednisone—hematologic cancer	1.69e-05	6.09e-05	CcSEcCtD
Doxepin—Confusional state—Epirubicin—hematologic cancer	1.69e-05	6.07e-05	CcSEcCtD
Doxepin—Diarrhoea—Dexamethasone—hematologic cancer	1.68e-05	6.05e-05	CcSEcCtD
Doxepin—Diarrhoea—Betamethasone—hematologic cancer	1.68e-05	6.05e-05	CcSEcCtD
Doxepin—Palpitations—Doxorubicin—hematologic cancer	1.68e-05	6.03e-05	CcSEcCtD
Doxepin—Oedema—Epirubicin—hematologic cancer	1.67e-05	6.02e-05	CcSEcCtD
Doxepin—Hypotension—Methotrexate—hematologic cancer	1.67e-05	6.01e-05	CcSEcCtD
Doxepin—Loss of consciousness—Doxorubicin—hematologic cancer	1.67e-05	6e-05	CcSEcCtD
Doxepin—Infection—Epirubicin—hematologic cancer	1.66e-05	5.98e-05	CcSEcCtD
Doxepin—Cough—Doxorubicin—hematologic cancer	1.66e-05	5.96e-05	CcSEcCtD
Doxepin—Shock—Epirubicin—hematologic cancer	1.65e-05	5.92e-05	CcSEcCtD
Doxepin—Convulsion—Doxorubicin—hematologic cancer	1.64e-05	5.92e-05	CcSEcCtD
Doxepin—Nervous system disorder—Epirubicin—hematologic cancer	1.64e-05	5.91e-05	CcSEcCtD
Doxepin—Thrombocytopenia—Epirubicin—hematologic cancer	1.64e-05	5.9e-05	CcSEcCtD
Doxepin—Hypertension—Doxorubicin—hematologic cancer	1.64e-05	5.89e-05	CcSEcCtD
Doxepin—Tachycardia—Epirubicin—hematologic cancer	1.63e-05	5.88e-05	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.63e-05	5.86e-05	CcSEcCtD
Doxepin—Skin disorder—Epirubicin—hematologic cancer	1.63e-05	5.85e-05	CcSEcCtD
Doxepin—Dizziness—Betamethasone—hematologic cancer	1.63e-05	5.85e-05	CcSEcCtD
Doxepin—Dizziness—Dexamethasone—hematologic cancer	1.63e-05	5.85e-05	CcSEcCtD
Doxepin—Hyperhidrosis—Epirubicin—hematologic cancer	1.62e-05	5.82e-05	CcSEcCtD
Doxepin—Insomnia—Methotrexate—hematologic cancer	1.62e-05	5.82e-05	CcSEcCtD
Doxepin—Myalgia—Doxorubicin—hematologic cancer	1.62e-05	5.81e-05	CcSEcCtD
Doxepin—Chest pain—Doxorubicin—hematologic cancer	1.62e-05	5.81e-05	CcSEcCtD
Doxepin—Arthralgia—Doxorubicin—hematologic cancer	1.62e-05	5.81e-05	CcSEcCtD
Doxepin—Anxiety—Doxorubicin—hematologic cancer	1.61e-05	5.79e-05	CcSEcCtD
Doxepin—Nausea—Triamcinolone—hematologic cancer	1.61e-05	5.79e-05	CcSEcCtD
Doxepin—Paraesthesia—Methotrexate—hematologic cancer	1.61e-05	5.78e-05	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.61e-05	5.77e-05	CcSEcCtD
Doxepin—Discomfort—Doxorubicin—hematologic cancer	1.6e-05	5.74e-05	CcSEcCtD
Doxepin—Anorexia—Epirubicin—hematologic cancer	1.6e-05	5.74e-05	CcSEcCtD
Doxepin—Dyspnoea—Methotrexate—hematologic cancer	1.6e-05	5.74e-05	CcSEcCtD
Doxepin—Somnolence—Methotrexate—hematologic cancer	1.59e-05	5.72e-05	CcSEcCtD
Doxepin—Dry mouth—Doxorubicin—hematologic cancer	1.58e-05	5.68e-05	CcSEcCtD
Doxepin—Hypersensitivity—Prednisone—hematologic cancer	1.58e-05	5.67e-05	CcSEcCtD
Doxepin—Dyspepsia—Methotrexate—hematologic cancer	1.58e-05	5.66e-05	CcSEcCtD
Doxepin—Hypotension—Epirubicin—hematologic cancer	1.56e-05	5.63e-05	CcSEcCtD
Doxepin—Vomiting—Dexamethasone—hematologic cancer	1.56e-05	5.62e-05	CcSEcCtD
Doxepin—Vomiting—Betamethasone—hematologic cancer	1.56e-05	5.62e-05	CcSEcCtD
Doxepin—Confusional state—Doxorubicin—hematologic cancer	1.56e-05	5.62e-05	CcSEcCtD
Doxepin—Decreased appetite—Methotrexate—hematologic cancer	1.56e-05	5.59e-05	CcSEcCtD
Doxepin—Rash—Betamethasone—hematologic cancer	1.55e-05	5.57e-05	CcSEcCtD
Doxepin—Rash—Dexamethasone—hematologic cancer	1.55e-05	5.57e-05	CcSEcCtD
Doxepin—Oedema—Doxorubicin—hematologic cancer	1.55e-05	5.57e-05	CcSEcCtD
Doxepin—Dermatitis—Betamethasone—hematologic cancer	1.55e-05	5.57e-05	CcSEcCtD
Doxepin—Dermatitis—Dexamethasone—hematologic cancer	1.55e-05	5.57e-05	CcSEcCtD
Doxepin—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.54e-05	5.56e-05	CcSEcCtD
Doxepin—Fatigue—Methotrexate—hematologic cancer	1.54e-05	5.55e-05	CcSEcCtD
Doxepin—Headache—Dexamethasone—hematologic cancer	1.54e-05	5.54e-05	CcSEcCtD
Doxepin—Headache—Betamethasone—hematologic cancer	1.54e-05	5.54e-05	CcSEcCtD
Doxepin—Infection—Doxorubicin—hematologic cancer	1.54e-05	5.54e-05	CcSEcCtD
Doxepin—Asthenia—Prednisone—hematologic cancer	1.54e-05	5.52e-05	CcSEcCtD
Doxepin—Pain—Methotrexate—hematologic cancer	1.53e-05	5.5e-05	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.53e-05	5.49e-05	CcSEcCtD
Doxepin—Shock—Doxorubicin—hematologic cancer	1.52e-05	5.48e-05	CcSEcCtD
Doxepin—Nervous system disorder—Doxorubicin—hematologic cancer	1.52e-05	5.46e-05	CcSEcCtD
Doxepin—Thrombocytopenia—Doxorubicin—hematologic cancer	1.52e-05	5.46e-05	CcSEcCtD
Doxepin—Pruritus—Prednisone—hematologic cancer	1.51e-05	5.45e-05	CcSEcCtD
Doxepin—Insomnia—Epirubicin—hematologic cancer	1.51e-05	5.45e-05	CcSEcCtD
Doxepin—Tachycardia—Doxorubicin—hematologic cancer	1.51e-05	5.44e-05	CcSEcCtD
Doxepin—Skin disorder—Doxorubicin—hematologic cancer	1.51e-05	5.41e-05	CcSEcCtD
Doxepin—Paraesthesia—Epirubicin—hematologic cancer	1.5e-05	5.41e-05	CcSEcCtD
Doxepin—Hyperhidrosis—Doxorubicin—hematologic cancer	1.5e-05	5.39e-05	CcSEcCtD
Doxepin—Dyspnoea—Epirubicin—hematologic cancer	1.49e-05	5.37e-05	CcSEcCtD
Doxepin—Somnolence—Epirubicin—hematologic cancer	1.49e-05	5.35e-05	CcSEcCtD
Doxepin—Anorexia—Doxorubicin—hematologic cancer	1.48e-05	5.31e-05	CcSEcCtD
Doxepin—Feeling abnormal—Methotrexate—hematologic cancer	1.47e-05	5.3e-05	CcSEcCtD
Doxepin—Dyspepsia—Epirubicin—hematologic cancer	1.47e-05	5.3e-05	CcSEcCtD
Doxepin—Diarrhoea—Prednisone—hematologic cancer	1.47e-05	5.27e-05	CcSEcCtD
Doxepin—Gastrointestinal pain—Methotrexate—hematologic cancer	1.46e-05	5.26e-05	CcSEcCtD
Doxepin—Nausea—Betamethasone—hematologic cancer	1.46e-05	5.25e-05	CcSEcCtD
Doxepin—Nausea—Dexamethasone—hematologic cancer	1.46e-05	5.25e-05	CcSEcCtD
Doxepin—Decreased appetite—Epirubicin—hematologic cancer	1.46e-05	5.24e-05	CcSEcCtD
Doxepin—Hypotension—Doxorubicin—hematologic cancer	1.45e-05	5.21e-05	CcSEcCtD
Doxepin—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.45e-05	5.2e-05	CcSEcCtD
Doxepin—Fatigue—Epirubicin—hematologic cancer	1.44e-05	5.19e-05	CcSEcCtD
Doxepin—Pain—Epirubicin—hematologic cancer	1.43e-05	5.15e-05	CcSEcCtD
Doxepin—Constipation—Epirubicin—hematologic cancer	1.43e-05	5.15e-05	CcSEcCtD
Doxepin—Urticaria—Methotrexate—hematologic cancer	1.42e-05	5.11e-05	CcSEcCtD
Doxepin—Dizziness—Prednisone—hematologic cancer	1.42e-05	5.09e-05	CcSEcCtD
Doxepin—Body temperature increased—Methotrexate—hematologic cancer	1.41e-05	5.09e-05	CcSEcCtD
Doxepin—Abdominal pain—Methotrexate—hematologic cancer	1.41e-05	5.09e-05	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.41e-05	5.08e-05	CcSEcCtD
Doxepin—Insomnia—Doxorubicin—hematologic cancer	1.4e-05	5.04e-05	CcSEcCtD
Doxepin—Paraesthesia—Doxorubicin—hematologic cancer	1.39e-05	5e-05	CcSEcCtD
Doxepin—Dyspnoea—Doxorubicin—hematologic cancer	1.38e-05	4.97e-05	CcSEcCtD
Doxepin—Feeling abnormal—Epirubicin—hematologic cancer	1.38e-05	4.96e-05	CcSEcCtD
Doxepin—Somnolence—Doxorubicin—hematologic cancer	1.38e-05	4.95e-05	CcSEcCtD
Doxepin—Gastrointestinal pain—Epirubicin—hematologic cancer	1.37e-05	4.92e-05	CcSEcCtD
Doxepin—Dyspepsia—Doxorubicin—hematologic cancer	1.36e-05	4.9e-05	CcSEcCtD
Doxepin—Vomiting—Prednisone—hematologic cancer	1.36e-05	4.9e-05	CcSEcCtD
Doxepin—Rash—Prednisone—hematologic cancer	1.35e-05	4.85e-05	CcSEcCtD
Doxepin—Dermatitis—Prednisone—hematologic cancer	1.35e-05	4.85e-05	CcSEcCtD
Doxepin—Decreased appetite—Doxorubicin—hematologic cancer	1.35e-05	4.84e-05	CcSEcCtD
Doxepin—Headache—Prednisone—hematologic cancer	1.34e-05	4.82e-05	CcSEcCtD
Doxepin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.34e-05	4.81e-05	CcSEcCtD
Doxepin—Fatigue—Doxorubicin—hematologic cancer	1.34e-05	4.8e-05	CcSEcCtD
Doxepin—Urticaria—Epirubicin—hematologic cancer	1.33e-05	4.78e-05	CcSEcCtD
Doxepin—Pain—Doxorubicin—hematologic cancer	1.33e-05	4.77e-05	CcSEcCtD
Doxepin—Constipation—Doxorubicin—hematologic cancer	1.33e-05	4.77e-05	CcSEcCtD
Doxepin—Abdominal pain—Epirubicin—hematologic cancer	1.32e-05	4.76e-05	CcSEcCtD
Doxepin—Body temperature increased—Epirubicin—hematologic cancer	1.32e-05	4.76e-05	CcSEcCtD
Doxepin—Hypersensitivity—Methotrexate—hematologic cancer	1.32e-05	4.74e-05	CcSEcCtD
Doxepin—Asthenia—Methotrexate—hematologic cancer	1.28e-05	4.62e-05	CcSEcCtD
Doxepin—Feeling abnormal—Doxorubicin—hematologic cancer	1.28e-05	4.59e-05	CcSEcCtD
Doxepin—Nausea—Prednisone—hematologic cancer	1.27e-05	4.57e-05	CcSEcCtD
Doxepin—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.27e-05	4.56e-05	CcSEcCtD
Doxepin—Pruritus—Methotrexate—hematologic cancer	1.27e-05	4.55e-05	CcSEcCtD
Doxepin—Hypersensitivity—Epirubicin—hematologic cancer	1.23e-05	4.44e-05	CcSEcCtD
Doxepin—Urticaria—Doxorubicin—hematologic cancer	1.23e-05	4.43e-05	CcSEcCtD
Doxepin—Abdominal pain—Doxorubicin—hematologic cancer	1.22e-05	4.4e-05	CcSEcCtD
Doxepin—Body temperature increased—Doxorubicin—hematologic cancer	1.22e-05	4.4e-05	CcSEcCtD
Doxepin—Diarrhoea—Methotrexate—hematologic cancer	1.22e-05	4.4e-05	CcSEcCtD
Doxepin—Asthenia—Epirubicin—hematologic cancer	1.2e-05	4.32e-05	CcSEcCtD
Doxepin—Pruritus—Epirubicin—hematologic cancer	1.18e-05	4.26e-05	CcSEcCtD
Doxepin—Dizziness—Methotrexate—hematologic cancer	1.18e-05	4.26e-05	CcSEcCtD
Doxepin—Diarrhoea—Epirubicin—hematologic cancer	1.15e-05	4.12e-05	CcSEcCtD
Doxepin—Hypersensitivity—Doxorubicin—hematologic cancer	1.14e-05	4.11e-05	CcSEcCtD
Doxepin—Vomiting—Methotrexate—hematologic cancer	1.14e-05	4.09e-05	CcSEcCtD
Doxepin—Rash—Methotrexate—hematologic cancer	1.13e-05	4.06e-05	CcSEcCtD
Doxepin—Dermatitis—Methotrexate—hematologic cancer	1.13e-05	4.05e-05	CcSEcCtD
Doxepin—Headache—Methotrexate—hematologic cancer	1.12e-05	4.03e-05	CcSEcCtD
Doxepin—Asthenia—Doxorubicin—hematologic cancer	1.11e-05	4e-05	CcSEcCtD
Doxepin—Dizziness—Epirubicin—hematologic cancer	1.11e-05	3.98e-05	CcSEcCtD
Doxepin—Pruritus—Doxorubicin—hematologic cancer	1.1e-05	3.94e-05	CcSEcCtD
Doxepin—Vomiting—Epirubicin—hematologic cancer	1.06e-05	3.83e-05	CcSEcCtD
Doxepin—Nausea—Methotrexate—hematologic cancer	1.06e-05	3.82e-05	CcSEcCtD
Doxepin—Diarrhoea—Doxorubicin—hematologic cancer	1.06e-05	3.81e-05	CcSEcCtD
Doxepin—Rash—Epirubicin—hematologic cancer	1.06e-05	3.8e-05	CcSEcCtD
Doxepin—Dermatitis—Epirubicin—hematologic cancer	1.05e-05	3.79e-05	CcSEcCtD
Doxepin—Headache—Epirubicin—hematologic cancer	1.05e-05	3.77e-05	CcSEcCtD
Doxepin—Dizziness—Doxorubicin—hematologic cancer	1.02e-05	3.68e-05	CcSEcCtD
Doxepin—Nausea—Epirubicin—hematologic cancer	9.95e-06	3.58e-05	CcSEcCtD
Doxepin—Vomiting—Doxorubicin—hematologic cancer	9.85e-06	3.54e-05	CcSEcCtD
Doxepin—Rash—Doxorubicin—hematologic cancer	9.77e-06	3.51e-05	CcSEcCtD
Doxepin—Dermatitis—Doxorubicin—hematologic cancer	9.76e-06	3.51e-05	CcSEcCtD
Doxepin—Headache—Doxorubicin—hematologic cancer	9.71e-06	3.49e-05	CcSEcCtD
Doxepin—Nausea—Doxorubicin—hematologic cancer	9.2e-06	3.31e-05	CcSEcCtD
Doxepin—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—IL6—hematologic cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MAPK8—hematologic cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TP53—hematologic cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—AKT1—hematologic cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—EP300—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TP53—hematologic cancer	1.36e-06	1.12e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—HRAS—hematologic cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	1.35e-06	1.11e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MYC—hematologic cancer	1.35e-06	1.11e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—EP300—hematologic cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—EP300—hematologic cancer	1.34e-06	1.1e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—EP300—hematologic cancer	1.34e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—PIK3CA—hematologic cancer	1.34e-06	1.09e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—SRC—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.33e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	1.33e-06	1.08e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—EP300—hematologic cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—HRAS—hematologic cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MYC—hematologic cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—ALB—hematologic cancer	1.31e-06	1.07e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	1.31e-06	1.07e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.31e-06	1.07e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—SRC—hematologic cancer	1.31e-06	1.07e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—SRC—hematologic cancer	1.3e-06	1.07e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—HRAS—hematologic cancer	1.3e-06	1.07e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—IL6—hematologic cancer	1.3e-06	1.07e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—ALB—hematologic cancer	1.3e-06	1.07e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.3e-06	1.06e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—SRC—hematologic cancer	1.3e-06	1.06e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.3e-06	1.06e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MYC—hematologic cancer	1.3e-06	1.06e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	1.29e-06	1.06e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—SRC—hematologic cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.28e-06	1.05e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.28e-06	1.05e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.28e-06	1.05e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TP53—hematologic cancer	1.28e-06	1.05e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.28e-06	1.04e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—VEGFA—hematologic cancer	1.28e-06	1.04e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—AKT1—hematologic cancer	1.27e-06	1.04e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	1.27e-06	1.04e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	1.27e-06	1.04e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.27e-06	1.03e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—STAT3—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—IL6—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—NRAS—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—STAT3—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—NRAS—hematologic cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	1.25e-06	1.03e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—STAT3—hematologic cancer	1.25e-06	1.03e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—NRAS—hematologic cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—KRAS—hematologic cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—IL6—hematologic cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—STAT3—hematologic cancer	1.24e-06	1.02e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—NRAS—hematologic cancer	1.24e-06	1.01e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.24e-06	1.01e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.24e-06	1.01e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.23e-06	1.01e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.23e-06	1e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.23e-06	1e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	1.23e-06	1e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	1.22e-06	9.95e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.21e-06	9.88e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MAPK3—hematologic cancer	1.21e-06	9.86e-06	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—AKT1—hematologic cancer	1.2e-06	9.83e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	1.2e-06	9.83e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	1.2e-06	9.8e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	1.2e-06	9.79e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.2e-06	9.78e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MYC—hematologic cancer	1.19e-06	9.77e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.19e-06	9.76e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.19e-06	9.74e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.19e-06	9.73e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	1.19e-06	9.7e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.18e-06	9.68e-06	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PIK3CA—hematologic cancer	1.18e-06	9.68e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.18e-06	9.64e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.18e-06	9.61e-06	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—IL6—hematologic cancer	1.17e-06	9.6e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MYC—hematologic cancer	1.17e-06	9.59e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.17e-06	9.59e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TGFB1—hematologic cancer	1.17e-06	9.57e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MYC—hematologic cancer	1.17e-06	9.56e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	1.17e-06	9.54e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MYC—hematologic cancer	1.17e-06	9.53e-06	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—AKT1—hematologic cancer	1.16e-06	9.51e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	1.16e-06	9.51e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.16e-06	9.5e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.16e-06	9.49e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.16e-06	9.47e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.16e-06	9.44e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MYC—hematologic cancer	1.15e-06	9.44e-06	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—AKT1—hematologic cancer	1.15e-06	9.42e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	1.15e-06	9.41e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.15e-06	9.41e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.15e-06	9.41e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.15e-06	9.41e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.15e-06	9.4e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.15e-06	9.39e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.15e-06	9.39e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.13e-06	9.22e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	1.12e-06	9.14e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.12e-06	9.14e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—ALB—hematologic cancer	1.11e-06	9.1e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.11e-06	9.09e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	1.11e-06	9.05e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.1e-06	9.03e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	1.1e-06	8.99e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.1e-06	8.99e-06	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—AKT1—hematologic cancer	1.09e-06	8.93e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTEN—hematologic cancer	1.09e-06	8.92e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.09e-06	8.88e-06	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.09e-06	8.88e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—KRAS—hematologic cancer	1.08e-06	8.86e-06	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	1.08e-06	8.85e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TP53—hematologic cancer	1.08e-06	8.84e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—KRAS—hematologic cancer	1.08e-06	8.83e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—KRAS—hematologic cancer	1.08e-06	8.81e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.07e-06	8.74e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.07e-06	8.74e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.07e-06	8.72e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—KRAS—hematologic cancer	1.07e-06	8.72e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.07e-06	8.71e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTEN—hematologic cancer	1.06e-06	8.7e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TP53—hematologic cancer	1.06e-06	8.7e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.06e-06	8.7e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.06e-06	8.69e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.06e-06	8.66e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—EP300—hematologic cancer	1.04e-06	8.5e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.03e-06	8.46e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.02e-06	8.36e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	1.02e-06	8.32e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.02e-06	8.32e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—EP300—hematologic cancer	1.02e-06	8.3e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.01e-06	8.29e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTEN—hematologic cancer	1e-06	8.2e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	9.98e-07	8.16e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	9.96e-07	8.14e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTEN—hematologic cancer	9.94e-07	8.13e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	9.93e-07	8.12e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	9.9e-07	8.1e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IL6—hematologic cancer	9.9e-07	8.09e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	9.9e-07	8.09e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	9.88e-07	8.08e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CB—hematologic cancer	9.83e-07	8.04e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TP53—hematologic cancer	9.81e-07	8.02e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	9.8e-07	8.01e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	9.78e-07	7.99e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	9.77e-07	7.99e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IL6—hematologic cancer	9.74e-07	7.96e-06	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—AKT1—hematologic cancer	9.67e-07	7.9e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TP53—hematologic cancer	9.66e-07	7.89e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TP53—hematologic cancer	9.63e-07	7.88e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TP53—hematologic cancer	9.6e-07	7.85e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TP53—hematologic cancer	9.57e-07	7.83e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—EP300—hematologic cancer	9.57e-07	7.82e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—EP300—hematologic cancer	9.48e-07	7.75e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TP53—hematologic cancer	9.48e-07	7.75e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TP53—hematologic cancer	9.45e-07	7.73e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—AKT1—hematologic cancer	9.44e-07	7.72e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—AKT1—hematologic cancer	9.39e-07	7.68e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—HRAS—hematologic cancer	9.38e-07	7.67e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—HRAS—hematologic cancer	9.23e-07	7.55e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—HRAS—hematologic cancer	9.21e-07	7.53e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—HRAS—hematologic cancer	9.18e-07	7.51e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.18e-07	7.51e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—HRAS—hematologic cancer	9.16e-07	7.48e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	9.13e-07	7.47e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	9.08e-07	7.42e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—HRAS—hematologic cancer	9.07e-07	7.41e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	9.04e-07	7.39e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	8.99e-07	7.35e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IL6—hematologic cancer	8.98e-07	7.34e-06	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—AKT1—hematologic cancer	8.87e-07	7.25e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IL6—hematologic cancer	8.84e-07	7.23e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IL6—hematologic cancer	8.82e-07	7.21e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IL6—hematologic cancer	8.79e-07	7.19e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TP53—hematologic cancer	8.78e-07	7.18e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IL6—hematologic cancer	8.76e-07	7.16e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	8.71e-07	7.12e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IL6—hematologic cancer	8.68e-07	7.09e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IL6—hematologic cancer	8.65e-07	7.07e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ALB—hematologic cancer	8.6e-07	7.03e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTEN—hematologic cancer	8.5e-07	6.95e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	8.4e-07	6.87e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—AKT1—hematologic cancer	8.29e-07	6.77e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.22e-07	6.72e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—AKT1—hematologic cancer	8.15e-07	6.67e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—AKT1—hematologic cancer	8.14e-07	6.65e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—AKT1—hematologic cancer	8.11e-07	6.63e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—EP300—hematologic cancer	8.1e-07	6.62e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—AKT1—hematologic cancer	8.08e-07	6.61e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL6—hematologic cancer	8.04e-07	6.57e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—AKT1—hematologic cancer	8.01e-07	6.54e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	7.98e-07	6.53e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.69e-07	6.29e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.59e-07	6.2e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CA—hematologic cancer	7.51e-07	6.14e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	7.42e-07	6.06e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CA—hematologic cancer	7.08e-07	5.78e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CA—hematologic cancer	7.01e-07	5.73e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTEN—hematologic cancer	6.56e-07	5.36e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—AKT1—hematologic cancer	6.28e-07	5.14e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—EP300—hematologic cancer	6.25e-07	5.11e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—AKT1—hematologic cancer	6.13e-07	5.01e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CA—hematologic cancer	5.99e-07	4.9e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—AKT1—hematologic cancer	5.78e-07	4.73e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—AKT1—hematologic cancer	5.73e-07	4.68e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—AKT1—hematologic cancer	4.9e-07	4e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.63e-07	3.78e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—AKT1—hematologic cancer	3.78e-07	3.09e-06	CbGpPWpGaD
